Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Thromboembolic potential of CDP7657 in an extended 3-month study in Rhesus monkeys

From: CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Dose group Total animals affected (%) Total affected lung sections Total examined lung sectionsa Lung sections affected (%)
Controlb 10 (50) 11 581 1.9
(n = 10/sex)
20 mg/kg 6 (60) 9 290 3.1
(n = 5/sex)
50 mg/kg 4 (40) 4 294 1.4
(n = 5/sex)
200 mg/kg 3 (33) 3 261 1.2
(n = 5/sex)
  1. Thromboembolic events defined as the occurrence of a thrombus or an organizing thrombus (intimal hyperplasia was not observed in this study); atotal number of lung sections examined in each group = 29/animal; btreated with i.v. saline